Tykerb (lapatinib) — United Healthcare
Chordoma
Initial criteria
- Diagnosis of recurrent conventional or chondroid chordoma
- AND Disease is EGFR-positive
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Tykerb therapy
Approval duration
12 months